期刊文献+

曲妥珠单抗1治疗HER-2过表达乳腺癌的研究进展 被引量:3

The Research Progress of Herceptin in Treatment of HER-2 Overexpressing Breast Cancer
下载PDF
导出
摘要 原癌基因的激活和抑癌基因的失活是肿瘤形成的重要分子机制.原癌基因HER-2是与乳腺癌的侵袭,转移及预后密切相关,HER-2过表达型乳腺癌进展快,预后差.近年来,针对HER-2结构构建具有靶向治疗作用的单克隆抗体药物曲妥珠单抗出现,显著提高了HER-2阳性晚期乳腺癌的疗效. Oncogene activation and inactivation of tumor suppressor genes is an important molecular mechanism of tumor formation. HER-2 oncogene is associated with breast cancer invasion and metastasis and prognosis, HER-2 overexpressing breast cancer progresses rapidly and has poor prognosis. In recent years, the emergence of targeted therapeutic monoclonal antibody drug Herceptin which built its structure for the HER-2 has significantly inproved HER-2-positive advanced breast cancer.
出处 《昆明医科大学学报》 CAS 2013年第12期145-148,共4页 Journal of Kunming Medical University
基金 国家自然科学基金资助项目(81360069) 云南省自然科学基金资助项目(2010CD196)
关键词 乳腺癌 HER-2基因 曲妥珠单抗 靶向治疗 Breast cancer Her-2 gene Herceptin Targeted therapy
  • 相关文献

参考文献7

二级参考文献84

  • 1郭瑞霞,魏丽惠.磷脂酰肌醇3激酶/蛋白激酶B信号传导通路与妇科恶性肿瘤关系的研究进展[J].中华妇产科杂志,2005,40(5):358-360. 被引量:22
  • 2Singer CF,Kostler WJ,Hudelist G.Predicting the efficacy of trastuzumab-based therapy in breast cancer:Current standards and future strategies[J].Biochim Biophys Acta,2008,1786(2):105-113.
  • 3Clynes RA,Towers TL,Presta LG et al.Inhibitory Fc receptors modulate in vivo cytoxicily against tumor targets[J].Nat Med,2000,6(41:443-446.
  • 4Junttila TT,Akita RW,Parsons K,et al.Ligand-independent Her-2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941[J].Cancer Cell,20009,15f(5):429-440.
  • 5Molina MA,Codony-Servat J,Albanell J,et al.Trastuzumab (herceptin),a humanized anti-Her-2 receptor monoclonal antibody,inhibits basal and activated Her-2 ectodomain cleavage in breast cancer cells[J].Cancer Res,2001,61(12):4744-4749.
  • 6Kostler WJ,Schwab B,Singer CF,et al.Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer[J].Clin Cancer Res,2004,10(5):1618-1624.
  • 7Nagata Y,Lan KH,Zhou X,et al.PTEN activation contributes to tumor inhibition by trastuzumah,and loss of PTEN nredicts trastuzumah resistance in patients[J].Cancer Cell,2004,6(2):117-127.
  • 8Izumi Y,Xu L,Di TE,et al.Tumour biology:herceptin acts as an anti-angiogenic cocktail[J].Nature,2002,416(6878):279-280.
  • 9Lane HA,Beuvink J,Motoyama AB,et al.ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)Cdk2 complex formation:receptor overexpression does not determine growth dependency[J].Mol Cell Biol,2000,20(9):3210-3223.
  • 10Saal LH,Holm K,Maurer M.et al.PIK3CA mutations correlate with hormone receptors,node metastasis,and ERBB2.and are mutually exclusive with FTEN loss in human breast carcinoma[J].Cancer Res,2005,65(7):2554-2559.

共引文献31

同被引文献32

引证文献3

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部